Spectrum Pharma (SPPI) Pharmaceuticals Provides Update on ROLVEDON, Reports Q4

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. LSTR
9. UPS
10. KIDS

Go back to Spectrum Pharma (SPPI) Pharmaceuticals Provides Update on ROLVEDON, Reports Q4

Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results

January 31, 2023 7:00 AM EST

-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million --

-- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 --

BOSTON--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.

Business Highlights and Preliminary, Unaudited Financial Results

Preliminary unaudited net sales for the quarter... More